alexa Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients.
Infectious Diseases

Infectious Diseases

Journal of AIDS & Clinical Research

Author(s): Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U, , Williams J, Sayles HR, Meza JL, Sayre P, Sandkovsky U,

Abstract Share this page

Abstract AIM: To gauge patient interest in receiving long-acting injectable nanoformulated antiretroviral therapy. METHODS: Four hundred adult HIV-infected patients currently prescribed antiretroviral therapy were surveyed. χ(2) tests were used for comparisons of interest across groups. RESULTS: Respondents were 68\% male and 53\% African-American, with a mean age of 47 years. Overall, 73\% of patients indicated that they would definitely or probably try injectable nanoformulated antiretroviral therapy; 61\% with weekly dosing; 72\% every 2 weekly; and 84\% monthly. In total, 48\% indicated that they were very concerned about the possible side effects and 35\% were very concerned about needle use. CONCLUSION: The majority of respondents indicated that they definitely or probably would try parenteral nanoformulated antiretroviral therapy.
This article was published in Nanomedicine (Lond) and referenced in Journal of AIDS & Clinical Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version